Browse drugs

…y people globally, requiring alternative management strategies. Psilocybin is gaining attention for its potential in chronic pain manageme…

… decline. Grief- and peace-related themes were prominent during psilocybin sessions. While six participants rated the treatment favourably…

…h is where psychedelics propose an additional alternative path. Psilocybin has recently shown promise in treating major depressive disorde…

… quality of life and autonomy, as well as illness trajectories. Psilocybin, when administered in high doses within a structured therapeuti…

…onists at serotonin 5-HT2A receptors in the brain; they include psilocybin, 5-methoxydimethyltryptamine, and N,N-dimethyltryptamine (trypt…

…as agonists at serotonin 5-HT2A receptors in the brain, include psilocybin, 5-methoxydimethyltryptamine, and N,N-dimethyltryptamine (trypt…

… are not completely understood. The strongest evidence supports psilocybin for treatment resistant depression and MDMA for post-traumatic …

… intervention, participants will attend an in-person supervised psilocybin session, receiving a standardised 25 mg dose. Primary outcomes …

…d shapes and colours after participating in a clinical trial of psilocybin for treatment-resistant depression. She continued to have ongoi…